Tag Archive for: Roche

PD-L1 blocks PD-L1 and B7.1 receptors on T cells thus triggering inactivation of cytotoxic T cells. © Genbentech Inc
Approval

Roche withdraws checkpoint blocker from the market

Roche AG’s US subsidiary Genentech Inc has withdrawn its checkpoint inhibitor atezolizumab from the market after disappointing results in bladder cancer.

Read more
©Roche
Roche

Ring exchange at Roche’s top executive level

Schwan follows Franz, Schinecker follows Schwan.

Read more